The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients

被引：0
|
作者：
Elisabetta Munzone
Alessandra Fabi
Giuseppe Buono
Roberta Caputo
Emilia Montagna
Mara Negri
Francesco Nuzzo
Antonella Palazzo
Ida Paris
Luca Conti
Anna Baggi
Jean Marie Franzini
Michelino De Laurentiis
机构：
[1] Istituto Europeo di Oncologia,Precision Medicine Unit in Senology
[2] IRCCS,Medical Oncology Unit Fondazione
[3] Fondazione Policlinico Universitario Agostino Gemelli,Ginaecological Oncology Unit Fondazione
[4] National Cancer Institute “Fondazione Pascale”,Life Sciences Division
[5] Policlinico Universitario Agostino Gemelli,undefined
[6] Policlinico Universitario Agostino Gemelli,undefined
[7] Business Integration Partners,undefined
来源：
Drugs & Therapy Perspectives | 2023年 / 39卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：432 / 446
页数：14
相关论文
共 50 条
  • [41] Patient (pt) preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive early breast cancer (HER2+eBC): Interim analysis of the open-label, randomised cross-over PHranceSCa study
    O'Shaughnessy, J.
    Sousa, S. P.
    Cruz, J.
    Fallowfield, L. J.
    Auvinen, P.
    Pulido, C.
    Cvetanovic, A.
    Wilks, S.
    Ribeiro, L.
    Burotto, M.
    Klingbiel, D.
    Messeri, D.
    Alexandrou, A.
    Trask, P.
    Fredriksson, J.
    Stamatovic, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S42 - S42
  • [42] Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer
    Sandhya Mehta
    Jipan Xie
    Raluca Ionescu-Ittu
    Xiaoyu Nie
    Winghan J. Kwong
    Oncology and Therapy, 2023, 11 : 481 - 493
  • [43] Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+?Metastatic Breast Cancer
    Mehta, Sandhya
    Xie, Jipan
    Ionescu-Ittu, Raluca
    Nie, Xiaoyu
    Kwong, Winghan J.
    ONCOLOGY AND THERAPY, 2023, 11 (04) : 481 - 493
  • [44] heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer
    Kuemmel, Sherko
    Harper-Wynne, Catherine
    Park, Yeon Hee
    Franke, Fabio
    de Laurentiis, Michelino
    Schumacher-Wulf, Eva
    Eiger, Daniel
    Heeson, Sarah
    Cardona, Andres
    Ozyilkan, Ozgur
    Morales-Vasquez, Flavia
    Metcalfe, Ciara
    Hafner, Marc
    Restuccia, Eleonora
    O'Shaughnessy, Joyce
    BMC CANCER, 2024, 24 (01)
  • [45] ECONOMIC EVALUATION OF PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB plus DOCETAXEL FOR TREATMENT OF PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER AGAINST TREATMENT WITH TRASTUZUMAB plus DOCETAXEL plus PLACEBO, IN THE VENEZUELAN CONTEXT
    Romero, M.
    Huerfano, L. M.
    Acero, G.
    VALUE IN HEALTH, 2015, 18 (07) : A822 - A822
  • [46] A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer
    Xu, Dongdong
    Wu, Jiang
    Yu, Jing
    Yang, Yuqing
    Wen, Xinxin
    Yang, Jixin
    Wei, Hongliang
    Xu, Xiaolong
    Li, Yike
    Yang, Liu
    Wang, Lei
    Wang, Yijia
    Ma, Wen
    Li, Nanlin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [47] Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis
    Kuemmel, S.
    Tondini, C. A.
    Abraham, J.
    Nowecki, Z. I.
    Itrych, B.
    Hitre, E.
    Karaszewska, B.
    Juarez, A.
    Morales-Vasquez, F.
    Perez Garcia, J. M.
    Cardona-Huerta, S.
    Heinzmann, D.
    He, J.
    Duc, A. N.
    Crepelle-Flechais, A.
    Martin, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 103 - 103
  • [48] A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).
    Luis, Ines Maria Vaz Duarte
    Guo, Hao
    Barry, William Thomas
    Krop, Ian E.
    Wagle, Nikhil
    Lowe, Alarice
    Gore, Danielle
    Andrews, Chelsea
    Osmani, Wafa
    Isakoff, Steven J.
    Tung, Nadine M.
    Winer, Eric P.
    Lin, Nancy U.
    Freedman, Rachel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study
    Shao, Zhimin
    Tseng, Ling-Ming
    Huang, Chiun-Sheng
    Pang, Da
    Yang, Youngsen
    Li, Wei
    Liao, Ning
    Geng, Cuizhi
    Zhang, Qingyuan
    Xu, Binghe
    Liu, Donggeng
    Kwong, Ava
    Yu, Mandy
    Sun, Guofang
    Mobus, Volker
    Dent, Susan
    Arahmani, Amal
    Borthwick, Gillian
    Henot, Frederic
    von Minckwitz, Gunter
    Jiang, Zefei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 345 - 353
  • [50] Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study (vol 22, pg 85, 2021)
    Tan, A. R.
    Im, S-A
    Mattar, A.
    LANCET ONCOLOGY, 2021, 22 (02): : E42 - E42
12345